


Accepted Manuscript

Title: Seizure secondary to Bupropion extended release preparation: A report

Authors: Dheerendra Kumar Mishra, Ujwal Sardesai, Pali Rastogi, Ram Ghulam



PII: S1876-2018(17)30525-7
DOI: <http://dx.doi.org/doi:10.1016/j.ajp.2017.08.006>
Reference: AJP 1215

To appear in:

Received date: 29-7-2017

Please cite this article as: Mishra, Dheerendra Kumar, Sardesai, Ujwal, Rastogi, Pali, Ghulam, Ram, Seizure secondary to Bupropion extended release preparation: A report. Asian Journal of Psychiatry <http://dx.doi.org/10.1016/j.ajp.2017.08.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

TITLE PAGE

Seizure secondary to Bupropion extended release preparation: A report

Dheerendra Kumar Mishra¹, Ujwal Sardesai¹, Pali Rastogi¹, RamGhulam¹

¹ Department of Psychiatry, M. G. M. Medical College Indore M.P. 452001 India

Introduction

Bupropion is an antidepressant drug belonging to norepinephrine-dopamine reuptake inhibitor (NDRI) class (Stahl SM., 2000). Different preparations of Bupropion have been approved by Food and drug administration (FDA) for the treatment of a major depressive disorder such as immediate release (IR), sustained release (SR), and extended release (XL) preparations (Montvale et al, 2005).

Bupropion has some common side effects like dry mouth, nausea, stomach pain, headache, dizziness, sore throat, muscle pain, mild itching or skin rash, increased sweating, increased urination, or changes in appetite, weight loss or gain (Dwoskin LP et al. 2006). Seizure incidence is also been a reported side effect of this drug, however, reported as a dose dependent phenomena in literature (Shepherd G 2005). Seizure rate of sustained release formulation is estimated as 0.1% at dose 300 mg per day and at 450 mg/day ranged from 0.35%-0.44%, (Davidson J, 1989).

Also, most of the previous research has described seizure incidence with immediate release formulation and incidence of seizure with extended release formulation is reported rarely. Thus hereby we present a case of seizure secondary to extended relies on the formulation of Bupropion.

Case Presentation

Download English Version:

<https://daneshyari.com/en/article/4929731>

Download Persian Version:

<https://daneshyari.com/article/4929731>

[Daneshyari.com](https://daneshyari.com)